Adaptimmune Therapeutics plc

ADAPY

US00653A1079

Pharmaceuticals

Delayed OTC Markets Other stock markets 12:49:40 19/06/26 am AEST			5-day change	1st Jan Change
0.0400 ^USD	0.00%		+31.58%	+53.85%

19/05	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/11	Adaptimmune Therapeutics plc Announces CEO Changes	CI

Top Midday Decliners

Published on 10/21/2025 at 03:22 am AEDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Adaptimmune Therapeutics plc

19/05	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/11	Adaptimmune Therapeutics plc Announces CEO Changes	CI
18/11	Adaptimmune Therapeutics plc Announces Leadership Changes	CI
27/10/25	Evaxion Names Helen Tayton-Martin as Chief Executive Officer	MT
27/10/25	Adaptimmune Therapeutics plc(OTCPK:ADAP.Y) dropped from NASDAQ Composite Index	CI
25/10/25	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading	MT
24/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
23/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
22/10/25	European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	MT
21/10/25	Top Midday Decliners	MT
21/10/25	European Equities Close Mostly Higher in Monday Trading; UK Sentiment Sees 'Some of the Gloom Lift'	MT
21/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
20/10/25	Adaptimmune Therapeutics to Voluntarily Delist From Nasdaq	MT
18/10/25	European Equities Traded in the US as American Depositary Receipts Down in Friday Trading, Up for Week	MT
17/10/25	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

Chart Adaptimmune Therapeutics plc

Duration

Period

ADAPY: Dynamic Chart

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Employees

506

Sector

Pharmaceuticals

More about the company